KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Assets (2017 - 2025)

Amneal Pharmaceuticals has reported Non-Current Assets over the past 9 years, most recently at $1.8 billion for Q4 2025.

  • Quarterly results put Non-Current Assets at $1.8 billion for Q4 2025, down 7.66% from a year ago — trailing twelve months through Dec 2025 was $7.2 billion (down 9.3% YoY), and the annual figure for FY2025 was $1.8 billion, down 7.66%.
  • Non-Current Assets for Q4 2025 was $1.8 billion at Amneal Pharmaceuticals, roughly flat from $1.8 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for AMRX hit a ceiling of $2.5 billion in Q1 2022 and a floor of $1.8 billion in Q3 2025.
  • Median Non-Current Assets over the past 5 years was $2.3 billion (2023), compared with a mean of $2.2 billion.
  • Biggest five-year swings in Non-Current Assets: rose 4.12% in 2022 and later dropped 12.7% in 2024.
  • Amneal Pharmaceuticals' Non-Current Assets stood at $2.4 billion in 2021, then dropped by 1.32% to $2.4 billion in 2022, then dropped by 12.26% to $2.1 billion in 2023, then fell by 8.64% to $1.9 billion in 2024, then fell by 7.66% to $1.8 billion in 2025.
  • The last three reported values for Non-Current Assets were $1.8 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.8 billion (Q2 2025) per Business Quant data.